Reducing the Bottlenecks in the Drug Discovery Peptide Workflow — ASN Events

Reducing the Bottlenecks in the Drug Discovery Peptide Workflow (#347)

Cedric Rentier 1 , Elizabeth Denton 2
  1. Biotage Japan Ltd., Koto-ku, Tokyo, Japan
  2. Biotage LLC, Charlotte, NC, USA

Peptide synthesis workflow is a multi-step process which involves synthesis, purification, and evaporation to obtain the desired peptide product. This demands that the steps from amino acid building blocks to final purified peptide product proceed as efficiently and smoothly as possible. In the last decade or so, peptides became an important synthetic target in drug discovery as the need for these unique pharmaceutical agents tremendously increased thanks to the advances in structural biology, design, production, and analytical methods.

 

Once hit compounds are identified, validation and preliminary structure-activity relationships are assessed using synthetically produced compounds. To minimize reagent consumption and time invested, these peptides are typically synthesized on a very small scale and in very high throughput. However, traditional downstream processing approaches introduce a variety of bottlenecks that slow delivery of the compound library for evaluation.

 

Herein we present data featuring the latest innovation from Biotage designed specifically to improve the parallel peptide synthesis workflow, with particular focus at the purification stage.  The data will demonstrate that solid phase extraction can be a suitable replacement for traditional ether precipitation workflows without compromising peptide integrity, product yield, all the while potentially improving purity.

#AusPeptide2023